June 1, 2020 / 1:27 PM / a month ago

BRIEF-Iterum Therapeutics Announces Topline Results For A Phase 3 Clinical Trial Of Oral And IV Sulopenem

June 1 (Reuters) - Iterum Therapeutics PLC:

* ITERUM THERAPEUTICS ANNOUNCES TOPLINE RESULTS FOR A PHASE 3 CLINICAL TRIAL OF ORAL AND IV SULOPENEM IN COMPLICATED URINARY TRACT INFECTION

* ITERUM THERAPEUTICS ANNOUNCES TOPLINE RESULTS FOR A PHASE 3 CLINICAL TRIAL OF ORAL AND IV SULOPENEM IN COMPLICATED URINARY TRACT INFECTION

* ITERUM - SULOPENEM DID NOT ACHIEVE STATISTICAL NON-INFERIORITY RELATIVE TO ERTAPENEM IN SURE 2 CLINICAL TRIAL IN COMPLICATED UTI

* ITERUM THERAPEUTICS PLC - SULOPENEM WAS WELL TOLERATED AND DEMONSTRATED A SAFETY PROFILE CONSISTENT WITH PREVIOUS STUDIES

* ITERUM THERAPEUTICS PLC - EVALUATING ITS CORPORATE, STRATEGIC AND FINANCIAL ALTERNATIVES

* ITERUM - STRATEGIC ALTERNATIVES COULD POTENTIALLY INCLUDE LICENSING, SALE OR DIVESTITURE OF ASSETS OR PROPRIETARY TECHNOLOGIES, A SALE OF COMPANY

* ITERUM THERAPEUTICS PLC - STRATEGIC ALTERNATIVES BEING EVALUATED COULD POTENTIALLY INCLUDE SEEKING PROTECTION UNDER BANKRUPTCY LAWS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below